Frailty proteomic signature

1. Frailty proteomic signature mediates cardiovascular disease in humans (proportion mediated: 49.18% (42.73%–53.40%)).

   “Mediation analyses revealed that the proteomic signature of physical frailty [natural indirect effect: 1.14 (1.12–1.15), proportion mediated: 49.18% (42.73%–53.40%)] and identified hub proteins (e.g., TNF, IL-1β, IL6) partially mediated the relationship between physical frailty and CVD.”

   Humansmediating the relationship between physical frailty and CVDn = 468,801

   Frailty reversal is linked to lower heart disease risk

   NPJ aging·Oct 21, 2026

More on Cardiovascular disease

1. Frailty proteomic signature raises the risk of cardiovascular disease in humans (HR 1.60, 95% CI 1.56–1.64).

   “The constructed proteomic signature was positively associated with CVD risk (HR per SD increase: 1.60; 95% CI: 1.56–1.64).”

   Humansn = 468,801

   Frailty reversal is linked to lower heart disease risk

   NPJ aging·Oct 21, 2026

More on Cardiovascular disease

1. Frailty proteomic signature raises the risk of chronic obstructive pulmonary disease in humans (HR 1.65, 95% CI 1.53 to 1.78).

   “Corresponding proteomic signature also related to increased risks of asthma (HR 1.22, 1.11 to 1.34) and COPD (1.65, 1.53 to 1.78).”

   Humans13.2 yearsn = 22,802

   Plasma proteomic biomarkers as mediators for the associations between frailty phenotypes and chronic respiratory diseases

   GeroScience·Feb 4, 2026

More on Chronic obstructive pulmonary disease

1. Frailty proteomic signature raises the risk of asthma in humans (HR 1.22, 95% CI 1.11 to 1.34).

   “Corresponding proteomic signature also related to increased risks of asthma (HR 1.22, 1.11 to 1.34)”

   Humans13.2 yearsn = 22,802

   Plasma proteomic biomarkers as mediators for the associations between frailty phenotypes and chronic respiratory diseases

   GeroScience·Feb 4, 2026

More on Asthma